Repeated thrombolysis for chronologically separated ischemic strokes: A case series

Stroke

Volumn 41, Issue 8, 2010, Pages 1829-1832

  Sauer, Roland ^a   Huttner, Hagen B ^a   Breuer, Lorenz ^a   Engelhorn, Tobias ^a   Schellinger, Peter D ^a   Schwab, Stefan ^a   Köhrmann, Martin ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

acute ischemic stroke; thrombolysis; tissue plasminogen activator

Indexed keywords

ALTEPLASE;

ACUTE DISEASE; ADULT; AGED; ALLERGIC REACTION; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CHRONOLOGY; CLINICAL ARTICLE; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; REPEAT PROCEDURE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; RECURRENCE; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77955172790     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.585067     Document Type: Article

References (10)

1. Zwickl CM, Hughes BL, Piroozi KS, Smith HW, Wierda D. Immunoge-nicity of tissue plasminogen activators in rhesus monkeys: antibody formation and effects on blood level and enzymatic activity. Fundam Appl Toxicol. 1996;30:243-254.
2. Katsutani N, Yoshitake S, Takeuchi H, Kelliher JC, Couch RC, Shionoya H. Immunogenic properties of structurally modified human tissue plas-minogen activators in chimpanzees and mice. Fundam Appl Toxicol. 1992;19:555-562.
3. Reed BR, Chen AB, Tanswell P, Prince WS, Wert RM Jr, Glaesle-Schwarz L, Grossbard EB. Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients. Thromb Haemost. 1990;64:276-280.
4. Cugno M, Cicardi M, Colucci M, Bisiani G, Merlini PA, Spinola A, Paonessa R, Agostoni A. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein. Thromb Haemost. 1996; 76:234-238.
5. Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S. Immu-nogenicity of recombinant DNA human insulin. Diabetologia. 1983;25: 465-469.
6. Rudolf J, Grond M, Prince WS, Schmulling S, Heiss WD. Evidence of anaphylaxy after alteplase infusion. Stroke. 1999;30:1142-1143.
7. Hill MD, Barber PA, Takahashi J, Demchuk AM, Feasby TE, Buchan AM. Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke. CMAJ. 2000;162:1281-1284.
8. Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, de Belder A, Davis J, Pitt M, Banning A, Baumbach A, Shiu MF, Schofield P, Dawkins KD, Henderson RA, Oldroyd KG, Wilcox R. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. 2005;353:2758-2768.
9. Meneveau N, Seronde MF, Blonde MC, Legalery P, Didier-Petit K, Briand F, Caulfield F, Schiele F, Bernard Y, Bassand JP. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest. 2006;129:1043-1050.
10. Topakian R, Gruber F, Fellner FA, Haring HP, Aichner FT. Thrombolysis beyond the guidelines: two treatments in one subject within 90 hours based on a modified magnetic resonance imaging brain clock concept. Stroke. 2005;36:e162-e164.